Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (Nasdaq: RIGL) on October 3, 2025 announced inducement equity awards under NASDAQ Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) on October 3, 2025 announced inducement equity awards under NASDAQ Listing Rule 5635(c)(4).
The company granted 41,138 stock options and 27,475 restricted stock units to 14 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the compensation committee under Rigel's Inducement Plan.
Details
News Market Reaction – RIGL
On Oct 3, the day this news came out, RIGL closed 1.49% above the previous close.
Data tracked by StockTitan Argus for the Oct 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302574356.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.